Alkem Laboratories Limited announced the acquisition of a 100% stake in Adroit Biomed Limited through a binding term sheet on February 7, 2025. The deal is valued at Rs 140 crore, payable in two tranches, subject to debt adjustments and changes in working capital as of the closing date.
Adroit Biomed Limited, a healthcare company focused on pharmaceuticals, nutraceuticals, and dermatology, reported a turnover of Rs 53.55 crore for FY24. The acquisition aims to boost Alkem’s presence in the dermatology and cosmetology segments by expanding its product portfolio, market penetration, and omnichannel presence.
The transaction is expected to be completed by April 1, 2025, or on a mutually agreed date.
Alkem Laboratories Limited reported its Q3 FY25 financial results, highlighting modest growth in revenue and profitability, supported by operational efficiencies.
Key Highlights – Q3 FY25 (YoY Comparison)
- Revenue from Operations: ₹3,374.28 crore, up 1.5% YoY from ₹3,323.87 crore
- Total Income: ₹3,467.27 crore, up 1% YoY from ₹3,417.51 crore
- Profit Before Tax (PBT): ₹731.07 crore, up 12% YoY from ₹654.90 crore
- Net Profit (PAT): ₹640.79 crore, up 6% YoY from ₹604.28 crore
